10x Genomics, Inc. TXG Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 69.6%+1.2pp | 69.1%+1.2pp | 68.8%+2.3pp | 69.5%+4.8pp | 68.4%+3.8pp | |
| Operating margin | -6.1%+21.5pp | -9.5%+22.4pp | -14.2%+17.5pp | -15.6%+24.5pp | -27.6%+16.3pp | |
| Net margin | -3.5%+21.6pp | -6.8%+23.1pp | -11.9%+17.1pp | -13.1%+24.8pp | -25.1%+17.1pp | |
| EBITDA margin | -0.1%+22.0pp | -3.9%+22.1pp | -8.8%+17.1pp | -10.4%+23.8pp | -22%+15.8pp | |
| Free cash flow margin | 19.1%— | 20.2%— | 12.7%— | 8.8%— | —— | |
| Returns | ||||||
| Return on equity | -3%+19.1pp | -5.8%+19.4pp | -10.1%+14.7pp | -11.3%+20.3pp | -22%+12.7pp | |
| Return on assets | -2.4%+14.8pp | -4.4%+14.9pp | -7.8%+11.6pp | -8.9%+16.1pp | -17.2%+10.1pp | |
| Return on invested capital | -9.5%+30.4pp | -14.3%+27.8pp | -21.5%+21.1pp | -22.4%+28.4pp | -39.9%+14.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | |
| Inventory turnover | 3×+0.5× | 2.9×+0.3× | 2.6×+0.2× | 2.5×-0.1× | 2.5×-0.2× | |
| Liquidity | ||||||
| Current ratio | 5.9×+0.5× | 4.5×-0.5× | 4.5×-0.4× | 5.8×+0.6× | 5.4×+0.2× | |
| Quick ratio | 5.4×+0.7× | 4.1×-0.2× | 4.1×-0.1× | 5.2×+0.8× | 4.7×+0.2× | |
| Cash ratio | 4.3×+0.8× | 3.1×+0.2× | 2.9×-0.3× | 3.5×+0.1× | 3.5×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $6.35+10.1% | $6.38+8.3% | $6.26+4.5% | $6.21+3.0% | $5.77-4.2% | |
| Valuation | ||||||
| Market capitalization | $2.71B+154% | $2.06B+18.7% | $1.46B-46.3% | $1.34B-42.3% | $1.07B-76.2% | |
| Enterprise value | $2.3B+199% | $1.67B+13.4% | $1.11B-53.7% | $1.03B-49.3% | $770.71M-81.7% | |
| Price / sales | 4.2×+2.5× | 3.2×+0.4× | 2.3×-2.0× | 2.1×-1.6× | 1.7×-5.5× | |
| Price / book | 3.3×+1.8× | 2.6×+0.1× | 1.9×-1.9× | 1.7×-1.5× | 1.5×-4.7× | |
| EV / sales | 3.6×+2.4× | 2.6×+0.2× | 1.7×-2.1× | 1.6×-1.6× | 1.2×-5.5× | |
| Free cash flow yield | 4.5%— | 6.3%— | 5.6%— | 4.2%— | —— | |
| Earnings yield | -0.8%+13.9pp | -2.1%+8.4pp | -5.2%+1.5pp | -6.3%+4.0pp | -14.7%-8.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are 10x Genomics, Inc.'s profit margins?
- 10x Genomics, Inc. (TXG) runs a 69.6% gross margin and a -6.1% operating margin, with a -3.5% net margin.
- Where do 10x Genomics, Inc.'s ratios come from?
- Every ratio is computed from 10x Genomics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.